4.7 Article

The Influence of the Intergranular Superdisintegrant Performance on New Drotaverine Orodispersible Tablet Formulations

期刊

PHARMACEUTICS
卷 15, 期 8, 页码 -

出版社

MDPI
DOI: 10.3390/pharmaceutics15082147

关键词

intragranular superdisintegrant; intergranular disintegrant; fast-dissolving granules; drotaverine orodispersible tablets; pharmacotechnical evaluation

向作者/读者索取更多资源

The study aims to investigate the impact of intergranular superdisintegrant on the properties of drotaverine hydrochloride fast-dissolving granules and orodispersible tablets. Orodispersible tablets were obtained by compressing the granules and excipient mixture. Different concentrations of superdisintegrant excipients were used to develop the tablets, which met the quality requirements in terms of friability, crushing strength, and disintegration time. The release of drotaverine from the tablets showed satisfactory results within the specified time.
The main objective of this study consists in establishing the influence of the intergranular superdisintegrant on the specific properties of drotaverine hydrochloride fast-dissolving granules (DROT-FDGs) and orodispersible tablets (DROT-ODTs). The orodispersible tablets were obtained by the compression of the FDGs and excipient mixture with an eccentric tableting machine. To develop DROT-ODTs, two types of superdisintegrant excipients in different concentrations (water-soluble soy polysaccharides (SSP) (1%, 5%) and water-insoluble soy polysaccharides-Emcosoy (R) STS IP (EMCS) (1%, 3%, 5%)) were used, resulting in five formulations (D1-D5). The DROT-FDGs and the DROT-ODTs were subjected to pharmacotechnical and analytical evaluation. All the orodispersible tablets obtained respect the quality requirements in terms of friability (less than 1%), crushing strength (ranging between 52 N for D2 and 125.5 N for D3), and disintegration time (<180 s). The in vitro release of drotaverine from ODTs showed that all formulations presented amounts of active substance released greater than 85% at 10 min. The main objective, developing 30 mg DROT-ODTs for children aged between 6 and 12 years by incorporating the API in FDGs, was successfully achieved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据